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Abstract: The protein p53, known as the “Guardian of the Genome”, plays an important role in
maintaining DNA integrity, providing protection against cancer-promoting mutations. Dysfunction of
p53 is observed in almost every cancer, with 50% of cases bearing loss-of-function mutations/deletions
in the TP53 gene. In the remaining 50% of cases the overexpression of HDM2 (mouse double minute 2,
human homolog) protein, which is a natural inhibitor of p53, is the most common way of keeping
p53 inactive. Disruption of HDM2-p53 interaction with the use of HDM2 antagonists leads to
the release of p53 and expression of its target genes, engaged in the induction of cell cycle arrest,
DNA repair, senescence, and apoptosis. The induction of apoptosis, however, is restricted to only a
handful of p53wt cells, and, generally, cancer cells treated with HDM2 antagonists are not efficiently
eliminated. For this reason, HDM2 antagonists were tested in combinations with multiple other
therapeutics in a search for synergy that would enhance the cancer eradication. This manuscript aims
at reviewing the recent progress in developing strategies of combined cancer treatment with the use
of HDM2 antagonists.
Keywords: HDM2 antagonist; MDM2; p53; p21; synergy; combined cancer treatment; targeted therapy;
chemotherapy; nutlin; RG7388; idasanutlin
1. Introduction
The protein p53 is a powerful regulator of cell fate. Together with a complex net of co-regulatory
proteins it integrates multiple stress signals and translates them into several programs, such as cell cycle
arrest, DNA-repair, senescence or apoptosis. One of the major roles fulfilled by p53 is the protection
against early cancerogenic events by the induction of repair mechanisms in response to DNA mutations
and by the controlled elimination of extensively damaged cells. For this reason, p53 protein has been
called the “Guardian of the Genome”. Not surprisingly, p53 is found functionally impaired in almost
every cancer type. Therefore, since the discovery of its tumor-suppressive potential, the strategies of
restoring its activity in cancer cells has become the Holy Grail of modern medicinal chemistry.
The progress in this field is best reflected by the development of small molecule antagonists of
HDM2 (mouse double minute 2, human homolog) protein. HDM2 (in mouse known as Mdm2) is an E3
ubiquitin ligase that binds p53, blocks its trans-activating activity, governs its nuclear export and targets
p53 to proteasomal degradation. While deactivation of p53 is a virtually obligatory step in cancer
development [1], it is estimated that around 50% of cancers contain non-mutated (wild type) TP53
genes, which encode a functional p53 protein. In those cells, however, the activity of p53 is blocked
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predominantly by the overexpression of HDM2 protein, frequently achieved by the duplication of the
HDM2 gene. In such cells, the administration of HDM2 antagonists results in forced dissociation of
HDM2-p53 complexes, releasing p53 from HDM2 inhibition [2]. Such a forced p53 release results in the
expression of a plethora of p53-regulated genes, presenting a transcriptome landscape similar, but not
identical to that of genotoxic p53 activation [3]. However, the blockade of HDM2 protein leads only to
partial activation of p53, and thus the outcome of such activation differs from the full p53 activation
process observed in response to genotoxic stress.
2. Limited Elimination of Cancer Cells by HDM2 Antagonists
It has been well documented that the activation of p53 by HDM2 antagonists results in the
inhibition of the growth of p53wt cancer cells, both in vitro and in mouse xenograft models. However,
while initially it has been expected that the activated p53 would lead to strong apoptosis in developed
p53wt cancers, with time, growing evidence pointed to serious limitations of this treatment strategy.
First, it soon became clear that HDM2 antagonists induce apoptosis only in a limited subset of p53wt
cells [4,5]. In many additional p53wt cell lines HDM2 antagonists induce cell cycle arrest, which is
more like reversible quiescence rather than irreversible senescence [6]. Although the growth inhibition
of cancer cells provides significant short-term therapeutic effects, the limited elimination of cancer cells
gives them the time necessary to gain new genetic or epigenetic features that lead to the generation
of secondary resistance. Such a phenomenon has been reported for almost every significant HDM2
antagonist [7–15]. Additionally, a recent study performed with the use of 113 p53wt cell lines showed
that 70 of them are naturally resistant to such a treatment [16].
The limited apoptosis upon p53 release by HDM2 antagonists likely results from distinctive modes
of p53 activity that leads either to cell cycle arrest and DNA repair or cell death. In the first mode,
the activation of p53 results in the induction of the expression of proteins engaged in cell cycle arrest,
such as p21 [17], and the proteins that assure negative feedback loops required for the generation
of p53 activation pulses, such as HDM2 and Wip-1 (wild-type p53-induced phosphatase 1) [18,19].
Cell cycle arrest is also partially related to the transcriptional downregulation of genes related to the
cell cycle. In this process, DREAM (dimerization partner, RB-like, E2F and multi-vulval class B) protein
complex acts as a transcriptional repressor by binding to E2F and CHR (cell cycle genes homology
region) elements. This p53-p21-DREAM pathway regulates the expression of over 250 genes, most of
which are involved in the cell cycle. Moreover, DREAM complex controls genes responsible for DNA
repair, telomere maintenance and chromosomal instability [20]. Given the nature of p53 in this mode,
it is called p53ARRESTER and is characterized by the phosphorylation at Ser15 and Ser20 residues [21].
The second mode requires additional phosphorylation of p53 at the Ser46 residue, resulting in a
so-called p53KILLER [22]. This version of p53 results in the induction of apoptosis at least partially
by the activation of a positive p53-PTEN (phosphatase and tensin homolog deleted on chromosome
ten)-Akt-HDM2 loop [23] and induction of the expression of pro-apoptotic Bax protein [24]. Such a
complex but fine regulation of p53 activity provides a tunable, coordinated response to DNA damage,
first giving the cell a chance to fix the damage, but eliminating the cell if the repair machinery should
have failed.
Since the transition from p53ARRESTER to p53KILLER requires the accumulation of HIPK2 kinase
(homeodomain-interacting protein kinase 2) in response to severe DNA damage [25] and normally
occurs after several cycles of the induction of p53ARRESTER protein [22,26,27], it is not easily achieved
by a rough p53 release evoked by HDM2 antagonists. Additionally, the forced release of p53 by HDM2
antagonists seem to be devoid of the proper cellular context and other mechanistic features, that is
required for enabling proapoptotic functioning of p53 [28]. Moreover, it was proposed that it is the
pulse of p53 activation in the G2 phase of the cell cycle which result in irreversible senescence of
DNA-damaged cell, while HDM2 antagonists arrest the cells predominantly in the G1 phase, where the
cells remain the potency of re-entering mitosis [29]. For these reasons, HDM2 antagonists require the
use of supporting agents that would provide synergistic therapeutic effects. In fact, besides a substantial
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work on the optimization of lead molecules [30,31], much effort has been done in the last ten years in the
field of the development of combined treatment strategies, that would incorporate HDM2 antagonists
into successful anti-cancer treatment regimes. The successful combinations attempt to support HDM2
antagonists most often by inducing natural DNA damage signaling (achieved with DNA-damaging
chemical agents or irradiation), blocking pro-survival or p53-inhibitory circuits (inhibitors of signaling
kinases, such as Akt, (protein kinase B) or phosphatases, such as Wip-1), or increasing proapoptotic
signaling in cancer cells (inhibitors of antiapoptotic proteins, TRAIL (TNF-related apoptosis-inducing
ligand) agonists etc.) (Figure 1).
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In this manuscript, we first shortly outline the most important and most potent HDM2 antagonists,
and then review the potential positive therapeutic interactions of these molecules with well-established
anti-cancer agents, grouped by the general mechanism of action of these agents (see also Table 1).
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Table 1. The summary of combination therapies of HDM2 antagonists.
Mode of Action
Combination
In Vitro Studies In Vivo Studies Clinical Trials ReferencesTherapeutic
Agent
HDM2
Antagonist
D
N
A
D
am
ag
e
5-azacitadine DS-3032b - - AML or MDS, Phase 1 NCT02319369
5-fluorouracil CGM097 neuroendocrine tumor cell lines - - [32]
acadesine nutlin-3a CLL - - [33]
busulfan idasanutlin neuroblastoma - - [34]
carboplatin
AMG-232 different tumor cell lines
osteosarcoma, colorectal
carcinoma, melanoma, NSCLC
xenograft mouse models
- [35]
APG-115 - - salivary gland carcinoma,Phase 1/2 NCT03781986
nutlin-3a breast cancer breast cancer xenograft mousemodels - [36]
cisplatin
AMG-232 different tumor cell lines
osteosarcoma, colorectal
carcinoma, melanoma, NSCLC
xenograft mouse models
- [35]
idasanutlin ovarian cancer, neuroblastoma - - [34,37]
MI-319 pancreatic cancer - - [38]
nutlin-3 nasopharyngeal carcinoma,adenocarcinoma, ovarian cancer - - [37,39–41]
nutlin-3a liposarcoma, RMS,neuroblastoma, osteosarcoma - - [42,43]
chlorambucil nutlin-3a CLL - - [33]
CPT-11 AMG-232 different tumor cell lines
osteosarcoma, colorectal
carcinoma, melanoma, NSCLC
xenograft mouse models
- [35]
cytarabine
ALRN-6924 - - AML and AMS, Phase 1 NCT02909972
CGM097 AML - - [44]
HDM-201 AML - AML, Phase 1/2 [44]NCT03760445
idasanutlin - - AML, Phase 1/2, Phase 3 NCT03850535NCT02545283
RG7112 - - AML, Phase 1 NCT01635296
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D
N
A
D
am
ag
e
daunorubicin
HDM-201 - - AML, Phase 1/2 NCT03760445
idasanutlin - - AML, Phase 1/2 NCT03850535
decitabine AMG-232 - - AML, Phase 1 NCT03041688
doxorubicin
AMG-232 different tumor cell lines
osteosarcoma, colorectal
carcinoma, melanoma, NSCLC
xenograft mouse models
- [35]
idasanutlin neuroblastoma - - [34]
nutlin-3a
DLBCL, CLL, PDAC,
liposarcoma, RMS and
osteosarcoma
DLBCL xenograft mouse models - [33,42,45,46]
etoposide
MI-219 lung cancer - - [47]
nutlin-3 ovarian cancer - - [41]
nutlin-3a PDAC, neuroblastoma - - [43,46]
fludarabine nutlin-3a CLL - - [33,48]
gemcitabine MI-63 MCL - - [49]
nutlin-3a PDAC - - [46]
idarubicin
CGM097
AML - - [44]
HDM-201
ionizing
radiation (IR)
AMG-232 - adenoid cystic carcinomaxenograft mouse models
glioblastoma, Phase 1,
soft tissue sarcoma,
Phase 1
[50]
NCT03107780
NCT03217266
RG7388 - RMS xenograft mouse models - [51]
nutlin-3 LSCC,glioblastoma - - [52,53]
oxaliplatin MI-219 PDAC, colonand breast cancer - - [54]
temozolomide
CGM097 neuroendocrine tumor cell lines - - [32]
idasanutlin neuroblastoma - - [34]
RG7775 neuroblastoma neuroblastoma mouse xenograftmodels - [55]
topotecan idasanutlin neuroblastoma - - [34]
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trabectedin RG7112 fibrosarcomaand liposarcoma - - [56]
D
N
A
D
am
ag
e
R
es
po
ns
e
Su
st
ai
ni
ng GSK2830371
ATSP-7041 Ewing sarcoma - - [57]
HDM-201
human melanoma - - [15]idasanutlin,
nutlin-3,
nutlin-3a osteosarcoma, breast, colonadenocarcinoma - - [58]
rucaparib idasanutlin ovarian cancer - - [59]
nutlin-3
A
po
pt
os
is
In
du
ct
io
n
B
C
L-
2
In
hi
bi
to
rs
ABT-263 SAR405838 ALL and AML ALL and AML xenograft mousemodels - [10]
ABT-737
MI-63 multiple myeloma multiple myeloma xenograftmouse models - [60–62]
nutlin-3 AML, CML - - [60,61]
B
C
L-
2
D
ow
re
gu
la
to
rs
oridonin nutlin-3 osteosarcoma - - [63]
venetoclax idasanutlin AML, neuroblastoma AML, neuroblastoma xenograftmouse models
AML patients,
Phase 1b/2
[64,65]
NCT02670044
venetoclax +
obinutuzumab
or rituximab
idasanutlin - - follicular lymphoma and DLBCL NCT03135262
SM
A
C
M
im
et
ic
s 1396-11
nutlin-3a AML - - [66]
ABT-10
SM-164 MI-219 lung cancer - - [47]
T
R
A
IL
A
go
ni
st
s
D269H/E195R nutlin-3 NSCLC, colon, ovarian cancer - - [67]
rhTRAIL
nutlin-3 NSCLC, colon, ovarian cancer - - [67]
nutlin-3a MPM - - [68]
RG7112 - MPM xenograftmouse models - [68]
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Pr
o-
Su
rv
iv
al
Si
gn
al
in
g
Pa
th
w
ay
s
Ta
rg
et
in
g
Ty
ro
si
ne
K
in
as
e
In
hi
bi
to
rs
alpelisib CGM097 AML - - [44]
HDM-201
buparlisib CGM097 AML - - [44]
HDM-201
ceritinib CGM097 neuroblastoma neuroblastoma xenograft mousemodels - [69]
dasatinib
nutlin-3 B-CLL - - [70]
nutlin-3a ALL - - [71]
gilterinib CGM097 AML - - [44]
HDM-201
ibrutinib nutlin-3 CLL CLL xenograftmouse models - [72]
imatinib nutlin-3a ALL - - [71]
midostaurin
CGM097 AML AML xenograftmouse models - [44,73]
HDM-201 AML - AML,Phase 1/2
[44]
NCT03760445
nilotinib
nutlin-3 AML, CML - - [60,61]
nutlin-3a ALL - - [71]
pictilisib CGM097 AML - - [44]
HDM-201
quizartinib
CGM097 AML AML xenograftmouse models - [73]
DS-3032b - - AML,Phase 1 NCT03552029
ruxolitinib KRT232 - - PV,Phase 2a/2b NCT03669965
sorafenib nutlin-3 AML, RCC - - [74,75]
R
as
/R
af
/M
EK
/M
A
PK
In
hi
bi
to
rs
AZD6244
CGM097 AML - - [76]
nutlin-3a AML - - [77]
dabrafenib AMG-232 different human cancer cell lines colorectal cancer xenograft mousemodels
melanoma,
Phase 1
NCT02110355
[78,79]
LGX818 CGM097 melanoma melanoma mouse models - [80]
PD0325901 AMG-232 different human cancer cell lines colorectal cancer xenograft mousemodels - [79]
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Pr
o-
Su
rv
iv
al
Si
gn
al
in
g
Pa
th
w
ay
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Ta
rg
et
in
g
R
as
/R
af
/M
EK
/M
A
PK
In
hi
bi
to
rs
pimasertib SAR405838 - - different tumor types, Phase 1 NCT01985191[81]
trametinib
AMG-232 different human cancer cell lines colorectal cancer xenograft mousemodels
AML, Phase 1b
melanoma, Phase 1
[78,79]
NCT02016729
NCT02110355
HDM-201 cutaneous melanoma - colorectal carcinoma,Phase 1
[82]
NCT03714958
idasanutlin
cutaneous melanoma - - [82]
nutlin-3
vemurafenib AMG-232 different human cancer cell lines colorectal cancer xenograft mousemodels - [79]
PI
3K
/A
kt
/m
T
O
R
In
hi
bi
to
rs
AMG511 AMG-232 different human cancer cell lines colorectal cancer xenograft mousemodels - [79]
AZD8055 AMG-232 different human cancer cell lines colorectal cancer xenograft mousemodels - [79]
BEZ235
AMG-232 different human cancer cell lines colorectal cancer xenograft mousemodels - [79]
Idasanutlin liposarcoma liposarcoma xenograft mousemodels - [83]
everolimus CGM097 neuroendocrine tumor - - [32]
GDC-0941 AMG-232 different human cancer cell lines colorectal cancer xenograft mousemodels - [79]
Ly294002 nutlin-3 ALL - - [84]
MK-2206 AMG-232 different human cancer cell lines colorectal cancer xenograft mousemodels - [79]
PI103 nutlin-3 AML - - [85]
perifosine nutlin-3 AML,B-CLL - - [86]
C
D
K
In
hi
bi
to
rs
abemaciclib nutlin-3a liposarcoma - - [87]
palbociclib idasanutlin liposarcoma
liposarcoma xenograft mouse
models - [88]
nutlin-3a liposarcoma - - [87]
ribociclib
HDM-201 - - liposarcomas,Phase 1b/2 NCT02343172
nutlin-3a liposarcoma - - [87]
Cancers 2019, 11, 1014 9 of 39
Table 1. Cont.
seliciclib
nutlin-3 neuroblasto-ma - - [89]
nutlin-3a
melanoma, breast,
colon adenocarci-noma,
liver carcinoma
- - [90]
PK
C
In
hi
bi
to
rs LXS196 HDM-201 - - metastatic uveal melanoma,Phase 1 NCT02601378
sotrastaurin CGM097 uveal melanoma uveal melanoma xenograft mousemodels - [91]
T
he
ra
pe
ut
ic
A
nt
ib
od
ie
s
A
nt
i-
PD
-1
an
d
A
nt
iP
D
-L
1
atezolizumab idasanutlin - - metastatic ER + breast cancer,Phase 1b/2 NCT03566485
pembrolizumab APG-115 - -
unresectable or metastatic
melanoma, advanced solid
tumors, Phase 1b/2
NCT03611868
spartalizumab HDM-201 - - colorectal cancer, RCCPhase 1 NCT02890069
A
nt
i-
C
D
20
obinutuzumab
nutlin-3 CLL - - [92]
idasanutlin MCL, DLBCL MCL, DLBCL mouse xenograftmodels
FL, DLBCL,
Phase 1b/2
[93]
NCT02624986
NCT03135262
rituximab
nutlin-3 CLL - - [92]
idasanutlin MCL, DLBCL MCL, DLBCL mouse xenograftmodels
FL, DLBCL,
Phase 1b/2
[93]
NCT02624986
NCT03135262
A
nt
i-
D
R
5
drozitumab nutlin-3a osteosarcoma,Ewing’s sarcoma - - [94]
M
is
ce
ll
an
eo
us
A
nt
i-
C
an
ce
r
A
ge
nt
s P
ro
te
as
om
e
In
hi
bi
to
rs
bortezomib nutlin-3 MCL, myeloma, breast, prostate,thyroid, colon cancer - - [95–97]
carfilzomib AMG-232 - - multiple myeloma, Phase 1 NCT03031730
ixazomib
citrate idasanutlin - - multiple myeloma, Phase 1/2 NCT02633059
MG-132 nutlin-3 schwannoma schwannoma xenograft mousemodels - [98]
H
D
A
C
s
In
hi
bi
to
rs SAHA idasanutlin AML - - [99]
VPA nutlin-3 AML
AML xenograft
mouse models - [100]
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M
is
ce
ll
an
eo
us
A
nt
i-
C
an
ce
r
A
ge
nt
s
A
nt
ib
io
ti
cs
actinomycin D nutlin-3
RMS
- -
[101]
different cancer
cell lines [102]
Z
in
c zinc MI-219 colon and breast cancer - - [38]
ZMC1 nutlin ovarian, lung, nasopharyngealcancer ovarian xenograft mouse models - [103]
H
SP
In
hi
bi
to
r
geldanamycin nutlin-3 AML - - [104]
A
T
P-
as
e
In
hi
bi
to
r
archazolid nutlin-3a liver, cervical, breast cancer,glioblastoma glioblastoma xenograft models - [105]
M
it
ot
ic
In
hi
bi
to
rs paclitaxel ALRN-6924 - -
advanced, metastatic, or
unresectable solid tumors,
Phase 1
NCT03725436
vincristine
nutlin-3 RMS - - [101]
RG7112 leukemia cell lines MLL-ALL xenograft mousemodels - [106]
O
th
er
s
metformin nutlin-3a malignant mesothelioma - - [107]
methotrexate nutlin-3a liposarcoma, RMS andosteosarcoma - - [42]
tanshinone IIA nutlin-3 AML - - [108]
P5091 ATSP-7041 Ewing sarcoma - - [57]
ALL—acute lymphocytic leukemia, AML—acute myeloid leukemia, AMS—advanced myelodysplastic syndrome, CLL—chronic lymphoblastic leukemia, CML—chronic myeloid leukemia,
DLBCL—diffuse large B-cell lymphoma, FL—follicular lymphoma, LSCC—laryngeal carcinoma, MCL—mantle cell lymphoma, MDS—myelodysplastic syndrome, MLL—mixed lineage
leukemia, MPM—malignant pleural mesothelioma, NSCLC—non- small cell lung carcinoma, PDAC—pancreatic ductal adenocarcinoma, PV—polycythemia vera, RCC—renal cell
carcinoma, RMS—rhabdomyosarcoma.
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3. The Most Significant Representatives of HDM2 Antagonists
Since the discovery of the first potent small-molecular inhibitors of HDM2-p53 interactions,
numerous chemical scaffolds have been published and tested [31,109]. Several promising compounds
are currently being tested in cancer-related clinical trials [30,110]. In general, these formulas are
designed using the three-finger pharmacophore model in which three substituents are selected to
mimic natural interaction between p53 and HDM2 proteins based on Phe19, Trp23 and Leu27 amino
acids of the p53 side chain (Figure 2) [111,112].
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H 7, 4JRG) s owed hat the two cis-oriented phenyl rings occupy Leu27 and Trp23 pockets,
whereas the alk xy gr up (isopropoxy i case of nutlin-3a and ethoxy in RG71 2) fits into Phe19
pocket. Further r search by Roche yielded the se nd ge eration compound RG7388 (idasan tlin),
which is bu lt on the pyrrolidine core [115]. The main optimization step, besides the core, was a
han e of the mu ual configuration of the phenyl rings from cis to tra s, which esulted in its reversed
occupation in th HDM2 subpockets. Further, to reduce exposure variability and increase th safety
and efficiency of idasanutlin, its PEGylated form was dev loped and tested (RG7775). Another s milar
inhibitor, AMG-232 was iscovered by Amgen Inc. (Thousand Oaks, California, USA) as a result of
rational design and optimization steps of the initi l lead structure [76]. The idea which lies behind
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piperidinone scaffold is similar to the ones of nutlins. The isopropyl substituent fills the Leu26 pocket,
whereas two trans-orientated chlorophenyl groups occupy the Trp23 and Phe19 pockets (PDB ID: 40AS).
Another numerous class of HDM2 antagonists are spiro-oxindole-3,3′-pyrrolidines, first discovered
by Ding et al. at the University of Michigan [116]. Further research yielded the compound MI-63 and
closely related MI-219 and MI-319 [117,118]. The analysis of the co-crystal structures of MI-63 analogs
suggests that the oxindole part tightly occupies the Trp23 pocket, the aliphatic neo-pentyl substituent
fits into Phe19 pocket, and substituted phenyl fits into the Leu26 pocket (for example see PDB ID:
3LBL). Further optimization of spiro-oxindoles led to the discovery of second-generation compounds
with reversed stereochemistry and increased affinity [119]. The co-crystal structure of MI-77301 with
HDM2 reveals the binding mode similar to its precursors, though it creates additional interactions
and induces refolding of the unstructured N-terminal region of HDM2 (PDB ID: 5TRF). Last years
provided a group of third-generation spiro-oxindoles, based on dispiropyrrolidine core. The most
potent representatives are APG-115 developed by Ascentage Pharma Group (Suzhou, China) [120]
and DS-3032b by Daiichi-Sankyo (Tokyo, Japan) [121].
Two additional classes of HDM2 antagonists, being currently tested in clinical trials, were
developed by Novartis (Basel, Switzerland). The design is based on the new, ‘central valine’ concept,
which reflects the idea of placing a planar-aromatic ring near the Val93 residue [122]. The first design
was based on the dihydroisoquinolinone core and led to the highly potent compound CGM097 [123]. In
its co-crystal structure, the molecule fits well into the classical binding pocket on the HDM2 surface (PDB
ID: 4ZYF). The Leu26 subpocket is occupied by the alkoxy derivative, the Trp23 subpocket is filled with
the 4-chlorophenyl substituent, and the elongated dialkylated aniline locates in the Phe19 subpocket.
Further development of the dihydroisoquinoline scaffold resulted in a new class of compounds with the
pyrazolo-pyrrolidinone core, represented by the HDM-201 (siremadlin) compound [124]. The rational
design enforced the pseudo-equatorial orientation of its 4-chlorophenyl moiety placed in the binding
pocket, and as such fulfilled the concept of the ‘central valine’ model.
Except for small-molecular inhibitors, there are examples of peptide and peptide-mimetics which
can interact with HDM2 protein. Noteworthy, one of them, ALRN-6924, discovered by Aileron
Therapeutics (Cambridge, Massachusetts, USA), is currently involved in several clinical trials [30].
Its structure is based on the idea of a p53-derived peptide chain, ‘stapled’ in a helical configuration by
the hydrocarbon chain. This approach is beneficial because (i) covalent modification is stabilizing the
α-helix of the peptide, (ii) the staple moiety protects the peptide from proteolytic degradation, and (iii)
cyclization enables the compound to cross the cell membrane. A molecule named as KRT232 delivered
by Kartos Therapeutics (Redwood City, California, USA) is in some clinical trials, though its structure
has not been disclosed.
4. Drug Combinations for the Supporting of Anti-Cancer Activity of HDM2 Antagonists
4.1. Combinations with DNA-Damaging Agents
DNA is the most important target for cancer chemotherapy due to the high division rate of
cancer cells and improper functioning of DNA repair mechanisms in those cells. For these reasons,
any factor causing DNA mutations, i.e., any genotoxic drug or ionizing radiation, would cause serious,
irreversible defects in the cell genome that would be more harmful to cancer cells than normal cells.
Since DNA damage itself induces a physiological p53 response, the addition of HDM2 antagonists to
DNA-damaged cells may assure a prolonged p53 activation by blocking HDM2-negative regulatory
loop. At the same time, DNA-damaging agents provide a complete activation of p53, which cannot be
achieved when HDM2 antagonists are used alone.
There are different mechanisms by which therapeutic agents induce DNA damage in the targeted
cancer cells (Figure 3) [125]. In this section, the combination therapies of p53/HDM2 antagonists with
DNA-damaging agents will be presented according to their mechanism of action.
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4.1.1. Alkylating Agents
Alkylating agents transfer alkyl-groups to DNA and form covalent bonds with nucleobases.
This affects the structure and dynamics of DNA, leading to the blockade of DNA replication and RNA
transcription, fragmentation of DNA by hydrolytic events and by malfunctions in the action of repair
enzymes, as well as nucleotide mispairing. All these events cause DNA damage response that can
potentiate the therapeutic effects of HDM2 antagonists.
There are different groups of alkylating agents [125]. Temozolomide (TMZ), which delivers methyl
groups to purine bases of DNA, results in the formation of N7-methylguanine and N3-methyladenine.
TMZ was evaluated in combination with RG7775 (idasanutlin prodrug) to treat neuroblastoma [55].
The combined treatment has led to the inhibition of tumor growth, which was correlated with the
upregulation of genes involved in apoptosis and signal transduction and downregulation of genes
involved in DNA replication, mitosis, cell cycle progression and cell division [55]. In another study,
TMZ showed an additive antiproliferative effect with HDM2 antagonist CGM097 in neuroendocrine
tumor model [32]. Furthermore, idasanutlin was combined with another alkylating agent—busulfan,
resulting in consolidation during frontline treatment in neuroblastoma cells [34]. Trabectedin,
the compound which alkylates guanine at the N2 position, leads to cell-cycle arrest and p53-mediated
apoptosis. This compound was combined with RG7112, which resulted in significant synergy in
liposarcoma cells [56].
4.1.2. Platinum Complexes
Platinum complexes are molecules that form covalent links between DNA nucleobases, bridged by
the platinum atom-containing moieties (a mechanism similar to that of alkylating agents) [126].
This forms monofunctional adducts or inter-strand, intra-strand, or DNA-protein crosslinks [127]. As a
consequence, DNA bending and inhibition of DNA replication and transcription are observed [125].
Despite many side effects of cisplatin, it was widely evaluated in many combination therapies
with p53/HDM2 antagonists. Combination treatment with cisplatin and nutlin-3a in sarcoma cell
lines revealed a clear synergism. It also reduced the negative genotoxic effects without significant
changes in antitumor activity. In nasopharyngeal carcinoma cells (NPC) the same therapy showed
that nutlin-3 made NPC cells more sensitive to cisplatin-related cytotoxicity; another study indicates
that non-small cell lung cancer cell lines are more prone to apoptosis after the combination therapy
administration [39,40,42]. The treatment with idasanutlin and cisplatin in p53wt neuroblastoma cell
lines resulted in increased apoptosis, which indicates the synergic effect. In ovarian cancer, the same
combination treatment had additive or even synergistic effect, which was confirmed by increased
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p53 activation, enhanced apoptosis and cell cycle arrest [34,37]. MI-319 in combination with cisplatin
presented increased cell growth inhibition and apoptosis in pancreatic cancer (PC) cells due to the
up-regulation of p73 protein, which has some overlapping anticancer activities with the p53 protein [38].
AMG-232 combined with cisplatin had notably increased antitumor efficacy in many different cancer
cell lines and also in the in vivo studies on mice [35].
Successors of cisplatin, carboplatin and oxaliplatin, were introduced to overcome side effects
and resistance to cisplatin [128]. Carboplatin is currently tested in combination with APG-115 in a
clinical trial on patients with salivary gland carcinoma (NCT03781986). Carboplatin was also combined
with AMG-232 [35], while oxaliplatin was evaluated in combination with MI-219 on p53wt Capan-2,
HCT-116, and MCF-7 cancer cell lines. In all these three types of tumors, the improved growth
inhibition was observed [54].
4.1.3. Antimetabolites
Antimetabolites are analogs of naturally occurring compounds that interfere with biochemical
processes essential for cell division and survival. Most antimetabolites used in cancer therapy have
nucleotide-related structure. These compounds either lead to the inhibition of nucleotide biosynthesis
or are incorporated into DNA molecules, leading to impaired DNA processing and mutations [125,129].
Antimetabolites are commonly used to treat cancer and tested also in combination with HDM2
antagonists. Some of the combinations have progressed to the clinical trials. As an example of
pyrimidine nucleoside analog, fludarabine (2-fluoro-ara-AMP) has synergic effect with nutlin-3a in
chronic lymphocytic leukemia (CLL) by increasing p53 levels, inducing Bax conformational changes
and apoptosis in p53wt cells [48]. Another antimetabolite, a purine nucleoside analog, cytarabine,
is currently under evaluation in combination with idasanutlin in patients with relapsed or refractory
acute myeloid leukemia (AML) (NCT02545283). This study has recently progressed to phase 3,
which makes idasanutlin the most advanced HDM2 antagonist in the clinical trials. Cytarabine is
also tested in clinical trials with daunorubicin and idasanutlin for safety and efficacy determination
in newly diagnosed patients with AML (NCT03850535). A study evaluating the combination of
RG7112 with cytarabine in patients with AML is already completed (NCT01635296). Yet another
HDM2 antagonist which is evaluated in combination with cytarabine in acute myeloid leukemia
or advanced myelodysplastic syndrome patients is stapled peptide ALRN-6924 (NCT02909972).
More pyrimidine analogs were also tested: 5-fluorouracil with CGM097 [32], gemcitabine with
nutlin-3a [46] and MI-63 [49], decitabine with AMG-232 (NCT03041688), and 5-azacitidine (AZA)
with DS-3032b (NCT02319369).
4.1.4. Topoisomerase Inhibitors
Topoisomerases (type I and type II) are enzymes that are involved in replication and transcription.
Their role is to relax supercoiled DNA. Drugs which target topoisomerases are commonly used to
treat cancer [125,130]. Topoisomerase inhibitors do not block the catalytic function of the enzyme,
but they “poison” them by weakening the enzyme ability to religate DNA and/or by increasing the
DNA cleavage [131].
Topotecan and doxorubicin, which are topoisomerase inhibitors, synergize with idasanutlin
in p53wt neuroblastoma cells [34]. In another study, irinotecan was combined with AMG-232 in
the colorectal carcinoma model. The combination therapy showed enhanced anti-cancer activity in
comparison to monotherapy [35]. Furthermore, a combination of the topoisomerase II inhibitor, etoposide,
with nutlin-3a led to enhanced activation of effector caspases [46]. Etoposide was also combined with
another HDM2 antagonist, MI-219. The combinatory treatment revealed that MI-219 synergizes with
etoposide by cytotoxicity enhancement and acceleration of the cell killing process [47]. Doxorubicin was
evaluated in combination with AMG-232 and nutlin-3a [33,35,45,46]. Another inhibitor from the same
class of drugs, daunorubicin, is under evaluation in clinical trials in combination with HDM-201 as
the first-line treatment of AML patients or in patients with relapsed/refractory AML (NCT03760445).
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Daunorubicin is also tested in combination with idasanutlin in newly diagnosed AML patients
(NCT03850535). Another anthracycline—idarubicin— was tested in vitro with CGM097. In the
experiment that the strongest therapeutic effect was achieved when AML cells lines were treated
with both agents [44].
4.1.5. Ionizing Radiation
Ionizing radiation (IR) is widely used in anti-cancer therapy. Many patients during the cancer
treatment receive ionizing radiation, that is either applied alone or in combination with anti-cancer
drugs [132]. The radiation has a direct or indirect impact on DNA damage [133]. Direct DNA damage
is caused by the introduction of DNA strand breaks, while indirect is mediated by the production
of reactive oxygen species (ROS), which in turn lead to many DNA modifications like formation of
abasic sites, DNA adducts, single-strand breaks (SSBs) and double-strand breaks (DSBs), DNA-protein
crosslinks, base oxidation and base deamination [125,134]. Despite the fact that radiation treatment
has many side effects [135], it is still a popular approach for the treatment of cancer, especially in
combination with therapeutic drugs.
Studies have indicated that IR induces HDM2 expression in a p53-dependent manner. Thus,
IR therapies were combined with HDM2 antagonists in an attempt to increase the activity of p53
protein [136]. Nutlin-3 induces senescence and radiosensitivity of laryngeal carcinoma cells (LSCC)
retaining wild-type p53 [52]. In another study, nutlin-3 radiosensitized lung cancer cells with wild-type
p53, resulting in cell cycle arrest and apoptosis after the combined treatment [137]. This combination
was also evaluated in human glioblastoma multiforme, where it resulted in increased apoptosis
and senescence. Furthermore, nutlin-3a strengthened the radiation response of glioma cell lines
harboring wild-type p53 [53]. Idasanutlin was combined with IR in two models of childhood
rhabdomyosarcoma, resulting in increased IR therapeutic efficiency [51]. Another small molecule
inhibitor, APG-115, was shown to provide the radiosensitization of p53 wild-type gastric cancer
cells. The combination of APG-115 with radiation resulted in cell cycle arrest and apoptosis of these
cells [138]. Moreover, AMG-232 is tested in combination with radiation in clinical trials on the patients
with glioblastoma (NCT03107780) and soft tissue sarcoma (NCT03217266). Radiation treatment in
combination with AMG-232 leads to enhanced tumor reduction. Combination of radiation with
AMG-232 was also evaluated in adenoid cystic carcinoma, resulting in tumor growth inhibition and
total regression that remained for months after the treatment [50].
4.2. Combinations with Drugs that Sustain DNA Damage Response
4.2.1. DNA Repair Inhibitors
Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme, which function is to repair DNA single-
strand breaks. PARP also plays a role in cell proliferation, differentiation, and transformation [139,140].
The pharmacological inhibition of PARP leads to the generation of double-strand breaks, which lead
to sustained genotoxic stress and apoptosis (Figure 3). One of the nonclinical studies focused on
combining nutlin-3a or idasanutlin with a PARP inhibitor, rucaparib, in ovarian cancer cell lines [59].
The combination was proved to be effective in p53wt ovarian cancer cell lines, where it induced
apoptosis and cell cycle arrest [59].
4.2.2. Phosphatases
Wip1 is a negative regulator of multiple DNA damage response proteins, such as p53,
CHK2 (checkpoint kinase 2), histone H2AX, and ATM (Ataxia telangiectasia mutated) (Figure 3) [141].
Overexpression of this protein has been observed in human cancers, particularly of breast and ovarian
origin [142]. A Wip1 inhibitor, GSK2830371, potentiated the cytotoxic effect of nutlin-3, idasanutlin,
and HDM-201, despite having no cytotoxic activity on its own [15]. The authors explained that the
inhibition of Wip1 phosphatase increases the activation of the ATM-mediated network to maintain
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the phosphorylated state of key proteins engaged in DNA damage response [15]. Another group
reports similar observations of nutlin-3 and GSK2830371, which when applied together increased
p53-mediated tumor suppression and induced senescence in MCF7, U2-OS and HCT116 cells [58].
Additionally, ATSP-7041, a stapled peptide postulated to act as a dual inhibitor of HDM2 and HDM4,
synergized with GSK2830371, triggering p53-mediated cell death in Ewing’s sarcoma [57].
4.3. Combinations with Apoptosis-Inducing Agents
The activation of p53 leads to apoptosis due to the disruption of the balance of pro- and
anti-apoptotic proteins (directly or per permeabilization of mitochondria’s membrane). This action,
however, requires the induction of p53KILLER mode, which mediates the expression of pro-apoptotic
proteins, such as Bax, Apaf-1, and Puma [21,143]. HDM2 antagonists are predominantly inducing
the p53ARRESTER mode, resulting in insufficient apoptosis. Additionally, the overexpression of
anti-apoptotic BCL-2 family proteins (i.e., BCL-2, BCL-X, MCL-1) may inhibit the proapoptotic effect
of p53 activation [144–146]. Thus, the inactivation/down-regulation of these antiapoptotic proteins
or increasing the proapoptotic signaling are rational strategies for enhancing the weak proapoptotic
potential of HDM2 antagonists (Figure 4).
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4.3.1. Selective BCL-2 Protein Inhibitors
Venetoclax (ABT-199/GDC-0199) is a BH3 (Bcl-2 homolog domain) mimetic, which selectively
inhibits BCL-2 protein. Venetoclax has revealed significant anti-tumor activity in both pre-clinical
and clinical studies [147–149]. The potency of the combined therapy of venetoclax with idasanutlin
was investigated both in vitro and in vivo on human cancer cell xenograft mice models of AML and
neuroblastoma. The venetoclax/idasanutlin treatment results in the robust down-regulation of the
anti-apoptotic protein MCL-1, which is also associated with the resistance to BH3 mimetics in a
single therapy [64,65]. This mechanism was proposed to explain the observed synergy of venetoclax
and idasanutlin treatment [64]. A phase 1b/2 clinical study with venetoclax in combination with
idasanutlin or cobimetinib (a MEK inhibitor [150]) for the treatment of AML patients is currently
running (NCT02670044). In addition, phase 1b/2 study aims to assess the dose-escalation and regimen of
venetoclax and idasanutlin in combination with monoclonal antibodies against CD20: obinutuzumab
for follicu r lymphom (FL), and rituximab for diffuse large B-cell lymphom (DLBCL) (NCT03135262).
ABT-737 is a BH3 inhibitor of BCL-2, BCL-XL, and BCL-W pr teins [151,152]. The combinations
of the compound with nultin-3 and MI-63 were investigated by Kojima et al., Gu et al. and Carter
et al. [60–62]. The scientists have confirmed that simultaneous t eatment with HDM2 antagonists
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and BCL-2 inhibitors results in greater induction of apoptosis and reduction of cell viability of AML
cells, multiple myeloma, and blast crisis myeloid leukemia cells. Moreover, it has been proved
that the synergistic effect of the combination therapy is independent of the cell cycle, even though
the cytotoxicity of each agent alone depends on the cell cycle’s phase [60–62]. In another study,
performed with acute lymphoblastic leukemia (ALL) and AML patients-derived cell lines, the sublines
resistant to BCL-2 inhibitors (ABT-737 and its orally active analog ABT-263—navitoclax) or MDM2
antagonist SAR405838 were developed. The results have shown that in both, the in vitro and in vivo
models of acute leukemia, there is no cross-resistance to BCL-2 and HDM2 inhibitors. The combination
of ABT-263 and SAR405838, both at 50 mg/kg, resulted in complete tumor regression in 100% of mice
for a period of 44 days, and this treatment regime was much more effective than the single agent
therapy [10].
4.3.2. Agents Downregulating the Level of Anti-Apoptotic BCL-2 Family Proteins
In addition to the compounds which directly bind BCL-2, combinations with agents that indirectly
downregulate the level of anti-apoptotic BCL-2 have been also reported. Nilotinib (AMN107, Tasigna),
a Bcr-Abl tyrosine kinase antagonist, inhibits the expression of anti-apoptotic BCL-2 proteins [153,154].
In the study designed by Carter et al., nutlin-3 sensitized the patients’ chronic myeloid leukemia cells to
nilotinib treatment, even though the cells were initially resistant to this drug [61]. Oridonin, a bioactive
constituent of a Chinese medicinal herb, which previously had been known as a modulator of BCL-2
levels in melanoma and leukemia, is a potent agent in combination therapy [155,156]. Nutlin-3/oridonin
treatment leads to robust apoptosis through a substantial increase in the proapoptotic/antiapoptotic
BCL-2 proteins ratio in p53wt osteosarcoma cells. Moreover, even though oridonin did not increase the
level of p53, HDM2, and Puma in the combined strategy nutlin-3 completely abolished the viability of
cancer cells. It has been revealed that the synergistic pro-apoptotic effect occurs due to the upregulation
of nutlin-3-triggered caspase activation and PARP cleavage [63].
4.3.3. SMAC Mimetic Compounds
SMAC (second mitochondria-derived activator of caspase) is a mitochondrial protein that promotes
cytochrome c-dependent caspase activation [157]. The mechanism of SMAC action is to promote
apoptosis due to the binding to the inhibitor of apoptotic proteins, IAPs, and blocking their inhibitory
activity. Thus, SMAC proteins promote the caspase activation in the cytochrome c/Apaf-1/caspase-9
pathway (Figure 4) [157]. So far, several human IAPs have been identified and one of the representatives
is known as the protein XIAP (X-linked inhibitor of apoptosis protein) [158].
It has been shown that the level of XIAP is regulated by HDM2 [159]. The hypothesis that the
combination of XIAP inhibitors and HDM2 antagonists may lead to the synergistic proapoptotic
effects in cancer cells has been verified. The study by Zheng and co-workers has demonstrated that
the small molecule XIAP inhibitor, SM-164, does not significantly enhance the potency of MI-219
against lung cancer cells [47]. On the contrary, another group has claimed that the concomitant
inhibition of XIAP and p53 activation promotes apoptosis in blasts from the patients with primary
AML. The mechanism of the synergy between nutlin-3a and ABT-10 (SMAC mimetic), and nutlin-3a
and 1396-11 compound (XIAP inhibitor) has been examined. The researches have revealed that
the treatment with either combination, ABT-10/nutlin-3a, and 1396-11/nutlin-3a, induced greater
activation of apoptosis signaling pathways and more strongly decreases p21 level via the caspase
cleavage, as a result of XIAP inhibition [66]. Also, the cytosolic release of SMAC and increase of
effector caspase-6 following the inhibition of HDM2 were found to be responsible for the increased cell
sensitivity to XIAP inhibition [66].
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4.3.4. TRAIL Agonists
TRAIL (TNF-related apoptosis-inducing ligand) is a member of the TNF (tumor necrosis factor)
family of cytokines, which acts as one of the most principal extracellular activators of apoptosis [160–162].
TRAIL ligand has an affinity to five receptors, among which DR4 (TRAIL-R1) and DR5 (TRAIL-R2) are
able to transmit the apoptotic signal [161,163]. The binding of TRAIL to the death receptors DR4 and
DR5 engages death-inducing signaling complex, DISC with Fas-associated death domain, FADD and
induces cleavage of caspase 8. As a consequence, the process leads to the activation of caspase 3 or the
engagement of the mitochondrial apoptotic pathway (Figure 4) [164,165].
Death receptors activate apoptosis pathway in vitro and in vivo after binding the recombinant
human TRAIL (rhTRAIL) [166–169]. rhTRAIL induces selective apoptosis in cancer cells and leaves
the normal cells unharmed [170,171].
The synergistic interactions of both nutlin-3 and rhTRAIL (dularemin) and nutlin-3 and
DR-5-selective TRAIL variant, D269H/E195R [172], have been estimated by the researchers in
Groningen [67]. The synergistic proapoptotic effect, induced by enhanced caspase 3 cleavage, has been
observed for both combinations. The study has shown that nutlin-3 increases the expression of
DR5 on the cell surface in p53wt human non-small cell lung carcinoma, ovarian cancer, and colon
cancer cell lines. Relating to this fact, the combination of nutlin-3 with D269H/E195R has been more
effective in inducing apoptosis than nutlin-3/rhTRAIL treatment. Furthermore, the nutlin-3/TRAIL
agonist/cisplatin triple combination treatment has been explored in the ex vivo tissue slice model of the
primary human ovarian cancer. Adding cisplatin as a genotoxic agent to the combination intensified
DR5-mediated apoptosis [67].
The combined targeting of HDM2 and TRAIL has also been reported in another study. Urso and
colleagues have investigated the synergy between nutlin-3 and rhTRAIL in malignant pleural
mesothelioma (MPM) cell lines and RG7112 and rhTRAIL in the in vivo MPM mouse model [68].
The authors speculated that the synergy between nutlin-3a and TRAIL results from the engagement
of mitochondrial apoptosis by TRAIL, accompanied by the increased DR5 expression and decreased
survivin expression in a response to HDM2 antagonist [68].
4.4. Combination with Therapy Selectively Targetting Pro-Survival Signaling Pathways
As our knowledge of the molecular basis of carcinogenesis increases, so do the possibilities of
designing new therapies for eradicating the disease. We now know that in cancer cells aberrations
occur in many cellular signaling pathways. These pathways regulate, among other processes, survival,
growth, and proliferation [173]. The approach to cancer treatment aiming at the selective targeting
of these pathways, designated as the targeted therapy, has gained considerable acceptance in the
past 20 years. Throughout these years, targeted monoclonal antibodies and synthetic small molecule
drugs were extensively tested, in many cases providing much more precise tools than chemotherapy,
radiotherapy or other conventional treatments [173–175].
Despite the wide range of anticancer drugs for targeted therapy and many successes in the
preclinical research, a great percentage of therapeutics does not provide satisfactory therapeutic
outcome when delivered to the patients as single agents [176]. Due to this fact, using two or more
agents at the same time as combination therapy became the standard of clinical practice. This also
accounts for HDM2 antagonists, since over-activated pro-survival pathways in cancer cells greatly
antagonize anti-cancer properties of p53 activation. For this reason, inhibition of pro-survival signaling
in cancer cells provides a strong synergism with p53-activating compounds (Figure 5).
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4.4.1. Inhibitors of Tyrosine Kinases
Tyrosine kinases transfer a phosphate from ATP to tyrosine residues in polypeptides. They function
either as extracellular receptors with di tinct domains responsible for ligan -binding and kinas activit ,
or on-receptor proteins located in the cytoplasm [177]. Tyrosi e kinase rec pt s are responsible for
initiation, transmission, and regulatio of m ny cellular pathways connected to cell proliferati n and
survival, such as JAK/STAT, PI3K/Akt/mTOR, and Ras/Raf/MEK/MAPK [177,178]. Tyrosine kinase’s
functions are tightly controlled, but due to mutations in cancer cells frequently their constant activation
occurs, providing an unrestrained flow f survival signaling [179].
Many tyrosine kinase inhibitors are currently teste in clinical trials, including several combinations
with HDM2 antagonists. FLT3 tyrosine kinase inhibitor, mi ostauri (PKC412), is tested in phase
1 and 2 clinical s udy for acute myeloid leukemia in combination with HDM-201 (NCT03760445).
One of the HDM2 tagonists, DS-3032b, is under evaluation in phase 1 clinical trial in combination
with quizartinib (NCT03552029). This study al o featured AML p ti nts, but only with FLT3 mutated
cancers. A additional phase 2a/2b clinical study, currently open for recruitment, focu es on combining
KRT232 with ruxolitinib, another inhibitor of tyrosine ki se receptor, which causes an indirect
inhibition of JAK/STAT signaling (NCT03669965).
Ibrutinib is a novel inhibitor of Bruton’s tyrosine kinase present on B-cells [180]. This inhibitor has
been used in combination w th nutlin-3 and has exerted a synergistic anti-cancer effect on p53wt and
p53mut B-leukemi cells [72]. This p53-independent mechanism might be med ated by other proteins
from the p53 family, such as p63 and p73 [181]. This eff ct occurred mainly due to apoptosis induc ion
and cell cycle arr st. When nutlin-3 was combined with sorafenib, a multi-kinase inhibitor, a synergist c
cytotoxic effect was observed in AML cel lines [74]. Apart from t e common occ rrence of apoptosis
induction, Zauli e al. also observed an increase in autophagic cell de th upon the dual treatment [74].
Sorafenib was also used in combination with nutlin-3 in another study, which test d the c -treatment
in renal cell carcinoma models [75]. This treat ent resulted in increased apoptosis hat was attribu
o the increas d levels of proapoptotic PUMA protein when the soraf nib and nutlin-3 cotreatment
was applied [75]. Midostaurin, was shown to synergize with CG 097 in AML cell models lo g with
apoptosis inductio [51,73]. A more selective inh bitor of FLT3, quizartin b (ACC220), also showed
similar synergy [73]. CGM097 and HDM-201 in combination w th FLT3 inhibitors, midostaurin,
BKM1 0 (buparli ib), GDC-0941 (pictilisib), BYL719 (alpelisib) and ASP22 5 (gilterinib) also exhibited a
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moderate to strong synergistic response in AML cell lines [44]. Simultaneous activation of p53 by HDM2
blockade and ALK (anaplastic lymphoma kinase) inhibition worked synergistically in suppressing the
growth of different ALK-amplified or mutated neuroblastoma cell lines [69]. The researchers used
CGM097 and ceritinib, a second generation ALK inhibitor first in in vitro studies, which were then
followed by mouse xenograft experiments. The combination was effective and resulted in tumor
regression throughout the time of the treatment in three out of five models used. The authors point out
that HDM2 inhibition is especially valuable for the treatment of MYCN-amplified neuroblastoma cell
lines, as these cells show remarkable sensitivity to MDM2 antagonists in vitro [69].
4.4.2. Ras/Raf/MEK/MAPK Pathway Inhibitors
One of the best characterized cellular pathways in cell biology is the mitogen-activated protein
kinase pathway, composed of Ras/Raf/MEK/MAPK proteins. This pathway is responsible for many
critical functions of the cell response to extracellular stimuli, such as cytokines, growth factors or
mitogen binding to their receptors localized in the cell membrane [182,183]. The components of
this pathway play a very important role in the genesis of cancer, which has been reported many
times before [183–185]. p53 and the MAPK components are the most frequently mutated tumor
suppressor and oncogene pathways in human cancers [81]. For this reason, there is a great potential in
simultaneous targeting of these two pathways to provide useful therapeutic approaches. For example,
MEK inhibition seems to result in transcriptional and posttranscriptional downregulation of the HDM2
gene, which in turn leads to lower HDM2 protein levels and increased activity of p53 [186].
The inhibitors of the Ras/Raf/MEK/MAPK pathway are used in combination with various HDM2
inhibitors in four clinical trials, one of which is still recruiting. AMG-232 was tested in combination with
trametinib (GSK1120212), a selective MEK1 and MEK2 inhibitor in a phase 1b clinical trial on the AML
patients (NCT02016729). Another clinical study (NCT02110355) featured AMG-232 for the treatment
of metastatic melanoma along with trametinib and dabrafenib. The early data for AMG-232 combined
with trametinib or dabrafenib suggested promising pharmacokinetic properties and potential antitumor
activity [78]. HDM-201 has also been combined with trametinib in a clinical study for the treatment of
advanced/metastatic RAS/RAF mutant and p53wt colorectal carcinomas (NCT03714958). This phase
1 study sponsored by Centre Léon Bérard is currently recruiting and is estimated to be completed
in late 2020. A phase 1 clinical trial of yet another HDM2 antagonist, SAR405838 in combination
with pimasertib, a selective MEK1/2 inhibitor, has been conducted for the treatment of malignant
neoplasm (NCT01985191). The patients suffered from different tumor types, i.e., colorectal, lung,
melanoma. The trial has so far defined the maximum tolerated dose of the drugs in combination and
provided preliminary results on the antitumor activity of this combination [81].
Recently, Wu and co-workers confirmed the synergistic effect of trametinib with three different
HDM2/p53 interaction inhibitors—nutlin-3, idasanutlin, and HDM-201—in cutaneous melanoma
cell models [82]. All combinations resulted in a significant increase of p53 level as well as its
phosphorylation status. The authors propose that the synergy results from the sustained activation of
ATM following trametinib administration, which maintains high phosphorylation status and activity
of p53, released by HDM2 antagonists. As a result, increased levels of apoptotic and cell-cycle
arrested p53wt cells (but not p53mut) were also reported, showing a clear synergy of trametinib
with HDM2 antagonists [82]. A significant synergistic effect of combined HDM2/p53 and MEK
blockade on cell growth inhibition and apoptosis induction was observed by Zhang et al. in AML
cell lines [77]. This group used nutlin-3a and a second generation allosteric MEK1/2 inhibitor
AZD6244 (AstraZeneca, ARRY-142886, selumetinib), which showed high selectivity and anti-tumor
efficiency both in pre-clinical and clinical studies [187]. The MEK inhibitor itself has shown moderate
proapoptotic effect in OCI/AML3 and MOLM13 cells, which became significant upon combining
selumetinib with nutlin-3a [77]. CGM097 has been tested for synergy in combination with LGX818
(NVP-LGX818, encorafenib), a BRAF inhibitor [80]. The authors reported a strong synergistic
response to combination treatment in both the in vitro viability assays on BRAFmut melanoma cells,
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and tumor growth in vivo, to the point of long-lasting tumor regressions. The proposed rationale
for this synergism was the induction of a complementary set of anti-proliferative and apoptosis
stimulating molecules by the combination of the compounds, since CGM097 induces p21 and Bax
expression, while NVP-LGX818 causes the induction of p27 and Bim [80]. CGM097 seems to exhibit
a synergistic apoptotic effect also when combined with selumetinib [73].
4.4.3. PI3K/Akt/mTOR Pathway Inhibitors
PI3K/Akt/mTOR pathway has very important functions in controlling various cellular
processes. Among them are transcription and translation, metabolism, angiogenesis, cell cycle
and apoptosis [188,189]. These processes are important both in physiological and in pathological
conditions and are very often deregulated during cancer formation and progression [190].
Perifosine, a synthetic alkyl-phospholipid, which is known to inhibit Akt, has been combined
with nutlin-3 and showed increased antileukemic activity [86,191]. The combination has been tested
on six different leukemia cell lines and resulted in greater apoptosis and p53 protein expression
induction in p53wt cell lines [86]. Idasanutlin and BEZ235, a PI3K andmTOR inhibitor, elicited a strong
therapeutic response in well-differentiated/dedifferentiated liposarcomas, which corresponded with
consistent induction of apoptosis and p53 level upon the combined treatment [83]. These findings
were then confirmed on mouse xenograft models, in which the dual therapy caused significant
tumor regression [83]. A different research group has found that PI3K/mTOR inhibitor PI103
causes a reduction in p53 level, which has been raised when a combination with nutlin-3 was
applied [85]. Synergistic effects of HDM2 antagonist AMG-232 with many PI3K/Akt/mTOR and
Ras/Raf/MEK/MAPK inhibitors were also reported on twenty different human cancer cell lines and
in RKO tumor xenograft in vivo experiments [79]. A great therapeutic effect was observed upon
combining HDM2 antagonist AMG-232 with MEK inhibitor PD0325901 and PI3K inhibitor AMG511
in triple therapy [79]. Dual therapy with CGM097 and everolimus, a well-known mTOR inhibitor,
showed an additive antiproliferative effect on GOT1 cells [32].
4.4.4. CDK Inhibitors
Alterations in cell cycle control occur frequently in many types of human cancers. For this
reason, inhibitors of cyclin-dependent kinases (CDKs) became a very important group of anti-cancer
drugs [192]. In cancer cells, CDK regulatory pathways are constantly active, leading to the omission
of critical cell cycle checkpoints, uncontrolled growth, and proliferation [192].
One combination therapy using an HDM2/p53 interaction inhibitor and a CDK inhibitor has
made it into the clinical trials. HDM-201 has been combined with a selective CDK4/6 inhibitor
ribociclib (LEE011) from Novartis for the treatment of 74 adults with liposarcomas (NCT02343172).
This Phase 1b/2 study aims to assess the maximum tolerated dose and the safety and efficacy of the
combination for liposarcoma patients.
The possibilities of combining the inhibitors targeting HDM2 and CDKs are being continuously
explored in preclinical research. The combination of idasanutlin with palbociclib, a highly selective
inhibitor of CDK4/6 widely used in clinical trials, was reported to wield great antitumor properties
in dedifferentiated liposarcomas when compared to monotherapy [88]. Simultaneous treatment
caused a significant increase in apoptosis in the in vitro studies, which was later confirmed by
tumor volume regression in the in vivo experiments with a mice xenograft model of dedifferentiated
liposarcoma [88]. However, Sriraman et al. showed that in five different cell lines derived from
human liposarcoma, HDM2 inhibitor nutlin-3a and CDK4/6 inhibitors palbociclib, ribociclib and
abemaciclib not only fail to synergize, but even seem to antagonize each other’s therapeutic effects,
despite the co-amplification of HDM2 and CDK4 genes in the used models [87]. The authors
concluded that employing both therapies simultaneously may, in fact, be counterproductive and
result in an unfavorable outcome for patients [87]. These findings seem to contradict the previous
report by Laroche-Clary et al. [88]. Roscovitine (CY-202, seliciclib), a wide-range CDK inhibitor
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with strong activity towards CDK1, CDK2, CDK5, and CDK7, and weak towards CDK4 and CDK6,
showed a considerable synergy with nutlin-3a [90,193]. The effect was visible as an additive
reduction of cell viability and induction of p53-dependent apoptosis. The same researchers reported
that the effect was enhanced when combining nutlin-3a and roscovitine with DRB, an adenosine
analog [90]. Roscovitine and nutlin-3 were additionally found to pharmacologically synergize in
neuroblastoma [89].
4.4.5. PKC Inhibitors
Another class of protein kinases extensively studied in the context of cancer is the family of
Protein Kinases C (PKC), composed of at least twelve members [194,195]. Different isoenzymes of
PKC affect many cell functions, such as proliferation, migration, adhesion, survival and malignant
transformation, and are crucial players in carcinogenesis and maintenance of malignant phenotype of
cancer cells [194,196]. Overexpression of PKCs is often observed in cancer [194,197].
A therapeutic combination of LXS196, a small-molecule drug that binds and inhibits PKC,
andHDM-201 is being determined in the form of an active clinical trial in metastatic uveal melanoma
patients (NCT02601378). The combination of PKC inhibitor and HDM2 antagonists has been tested
for uveal melanoma also in nonclinical research. Co-treatment using CGM097 and a PKC inhibitor
sotrastaurin (AEB071) was reported by Carita et al. to decrease the tumor volume in patient-derived
xenograft mouse models [91]. The same tendency to stimulate cell death by apoptosis has also been
confirmed in uveal melanoma cell lines [91].
4.5. The Combination with Anti-PD-/PD-L1 and Anti-CD20 Therapeutic Antibodies
Monoclonal antibodies (mAbs) constitute a tremendous portion of anti-cancer agents.
Targeted therapies based on monoclonal antibodies that block numerous oncogenic pathways are
widely studied [198,199]. mAbs are the most successful therapeutic agents, for both, the solid
tumors [200], and leukemias or lymphomas [201]. The unprecedented potency of immunoglobulins
has been confirmed by hundreds of clinical trials (according to the 2017 GlobalData report [202]).
A number of combinations of HDM2 antagonists with monoclonal antibodies are undergoing
clinical trials. Among them, the therapies with mAbs targeting PD-1/PD-L1 interaction or
B-lymphocyte antigen CD20 have their primacy (Figure 5).
In June 2019 there have already been three 1b/2 phase clinical studies regarding the combination
of HDM2 with PD-1 or PD-L1 inhibitors. In 2016, Novartis Pharmaceuticals has started clinical trials
with the combination of HDM-201 and PDR001 (spartalizumab, anti-PD-1 antibody) to characterize
the dose escalation for colorectal cancer and renal cell carcinoma treatment (NCT02890069).
Pembrolizumab (Keytruda), another anti-PD-1 antibody approved by the FDA across a range of
cancers [203] is tested with APG-115 in patients with advanced solid tumors and unresectable or
metastatic melanomas (NCT03611868). Another active clinical trial involves the studies on the safety
and tolerability of idasanutlin in combination with atezolizumab (Tecentriq, anti-PD-L1 antibody, a
drug approved as a single therapy for various cancers [203]) and MEK inhibitor, cobimetinib. The
study has been running since 2018 and is currently in the recruitment phase for the patients who
suffer from metastatic estrogen receptor-positive breast cancer (NCT03566485).
Rituximab (MabThera®) and obinutuzumab (Gazyva®) are humanized anti-CD20 mAbs
characterized by a distinct mechanism of action. The scientists speculate on the superiority of these
two biologics over each other [204]. Pre-clinical data suggests that obinutuzumab is more efficient
than rituximab in depleting B cells [205] and has a better toxicological profile, while rituximab therapy
causes increased resistance generation [206,207]. Nevertheless, both mAbs have been approved for
cancer therapy.
Phase 1b/2 clinical trials of rituximab and obinutuzumab in combination with idasanutlin have
been conducted by Hoffmann-La Roche. The first study started in 2015 and involved the treatment
with idasanutlin and obinutuzumab in the FL patients and the idasanutlin/rituximab combination
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in DLBCL participants (NCT02624986). The second study is running and aims at determining the
regimen for idasanutlin and venetoclax (selective BCL-2 protein inhibitor, see the previous section)
in dual and triple combinations with obinutuzumab and with rituximab for FL and DLBCL patients
(NCT03135262).
In addition, the synergistic effect on cell death induction has been shown for obinutuzumab
and nutlin-3 in the preliminary in vitro studies with chronic lymphocytic leukemia cell lines [92].
Roche has strengthened the idea of combination therapy with anti-CD20 mAbs and HDM2
antagonist for the patients with CD20-positive B-cell malignancies. The study reported the combined
obinutuzumab/idasanutlin treatment to be superior to single therapy with mAb in mantle cell
lymphoma (MCL) and DLBCL xenograft models [93].
The efficacy of drozitumab, a human mAb against DR5 was evaluated in a combination
treatment with nutlin-3. HDM2 antagonist has augmented the apoptotic response to drozitumab
in vitro in a panel of sarcoma cell lines and ex vivo human sarcoma patients. The scientists have
postulated that the key factor that contributes to the synergistic effects between these molecules is
upregulation of DR5 receptor expression following the p53 activation [94]. However, the development
of drozitumab has been discontinued in 2010 [208].
4.6. The Combinations with Miscellaneous Anti-Cancer Agents
4.6.1. Proteasome Inhibitors
Proteasome serves as the main center of protein degradation in cells. The proteasome-dependent
degradation of tumor suppressors, such as p53 [188,190], and other proteins involved in anti-cancer
response (i.e., IκB and p44/42 MAPK) [209] is correlated with multiple types of cancer [210].
Therefore, inhibition of proteasome activity is a promising anti-cancer strategy (briefly reviewed
in [210,211]).
Bortezomib (Velcade®) was the first proteasome inhibitor designed and approved for cancer
treatment, more specifically for multiple myeloma patients [212]. The synergistic effect of bortezomib
in combination with HDM2 inhibitors has been evaluated on a variety of cancer types in vitro.
Bortezomib has exhibited anti-cancer activity against mantle cell lymphoma, and the addition of
nutlin-3 has resulted in synergistic cytotoxicity regardless of mutational p53 status in cancer cell
lines [97]. The p53-independent effect of the combination has been associated with an increased
level of p73 protein, a p53 homolog. p73-mediated induction of p21, Puma and Noxa expression
may account for the observed cell-cycle arrest and apoptosis [97]. An additive cytotoxic effect of
nutlin-3 and bortezomib has been reported on bortezomib-sensitive multiple myeloma (MM) cell
lines [95]. The authors explain that the combination of HDM2 inhibition and proteasome inhibition
not only increases the stability and levels of p53 but also blocks its ubiquitination and transcriptional
inactivation, thus making p53 more functional [95]. In another study, the scientists have shown the
synergistic cytotoxic activity of the compounds in MM cells. The authors report the induction of
apoptotic signaling defined as the cleavage of PARP, caspase-8 and caspase-3 and a modest cleavage
of caspase-9 [96]. Additionally, p53-induced repression of the anti-apoptotic protein, survivin was
observed [96]. In breast, prostate, colon, and thyroid cell lines, the nutlin-3/bortezomib combination
has triggered the synergistic cytotoxic effect. Furthermore, the scientists have postulated that,
as a consequence of nutlin-3 action, molecular pathways associated with poorer responsiveness to
bortezomib may be counteracted [95].
Ixazomib citrate and carfilzomib are next-generation proteasome inhibitors, that are used
in experimental combination therapies with HDM2 antagonists. Ixazomib citrate is currently
tested in a combination with idasanutlin and dexamethasone. Phase 1 and 2 clinical study is
performed to estimate optimum regimens in treating patients with MM that has returned after
a period of improvement (NCT02633059). National Cancer Institute conducts the phase 1 trial
studies on AMG-232 treatment when given together with carfilzomib and other drugs used in
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chemotherapy: lenalidomide and dexamethasone. The patients suffering from hypercalcemia,
plasmacytoma, recurrent plasma cell myeloma, and refractory cell myeloma are currently being
recruited (NCT03031730).
The effect of MG-132 (one of the early proteasome inhibitors) and nutlin-3 on schwannoma
cells has been assessed by Chen and colleagues. They have demonstrated that the differences
in the expression of merlin, which is a tumor suppressor protein, in cancer cultures explain the
functional diversity in response to nutlin-3 treatment [98]. It has been proved that dual therapy
of nutlin-3/MG-132 narrows the differences in the sensitivity to nutlin-3 in schwannoma cells. In
addition, in vivo experiment with human xenograft model of schwannoma has revealed that the
small-molecules work together to impose apoptosis [98].
4.6.2. Histone Deacetylase Inhibitors
Epigenetic regulation is also used as a possible therapeutic approach for cancer treatment. In this
therapy, histone deacetylases (HDAC) inhibitors play a major role, with several potent compounds
being tested in clinical trials [213]. Valproic acid (VPA) inhibits the action of class I HDACs [214].
The combination with nutlin-3 increased the level of apoptosis and autophagy in p53wt AML
cell line MOLM-13 and caused significant tumor regression in a MOLM-13 mouse model [100].
Suberoylanilide hydroxamic acid (SAHA, vorinostat, MK0683) is another HDAC inhibitor. It has been
used in combined therapy with idasanutlin, resulting in synergy in apoptosis induction in AML cell
lines regardless of their p53 status [99].
4.6.3. Antibiotics
Antibiotics are typically used to treat bacterial infections. However, some classes of antibiotics
inhibit the division of proliferating eukaryotic cells and thus are also explored in the therapy of
cancer [215–217]. Some compounds representative for this group of molecules were studied in
combination therapies with HDM2 antagonists. One example is actinomycin D, a well-known
transcription inhibitor widely used to treat cancer [218]. Actinomycin D inhibits RNA synthesis by
blocking DNA-dependent RNA polymerase. Nutlin-3 combined with actinomycin D resulted in the
enhancement of antitumor activity in rhabdomyosarcoma cells with wild-type p53 [101]. In another
study with the same combination, the synergic effect on cancer cell lines has been confirmed [102].
Nutlin-3a binds to HDM2 and releases p53, while actinomycin D stimulates p53 phosphorylation and
accumulation via a mechanism which engages HDM2 high expression. Authors have shown that the
combination therapy results in the enhanced p53 activation with phosphorylation of Ser46 residue,
which is a marker of proapoptotic p53KILLER mode [102].
4.6.4. Zinc
Zinc has an essential impact on p53. The p53 protein binds to DNA by a domain which
is stabilized by a zinc atom, which is why its role is so important in forming p53 DNA-binding
domain complex [219]. Metal chelators have the ability to remove zinc from p53, what in turn
leads to ‘mutant-like’ p53 form which cannot specifically bind to DNA [220]. Zinc has been tested in
combination with HDM2 inhibitor,MI-219, in colon and breast cancer cells. The scientists observed a
significant increase ofMI-219-induced apoptosis in the treated cells. Furthermore, this phenomenon
was reversible by a zinc chelator, TPEN (N,N,N′,N′-tetrakis(2-pyridinylmethyl)-1,2-ethanediamine),
which clearly suggests a crucial zinc role in this process [38].
Zinc metallochaperones (ZMCs) are a new class of mutant p53 reactivators [221]. In general,
the function of metallochaperones is to shuttle metal ions to intracellular proteins [222]. ZMCs
are small-molecule metal ion chelators that have the ability to donate zinc to mutant p53 which
lacks Zn2+ [221]. Many studies indicate that ionizing radiation and chemotherapy work better on
wild-type p53 tumors [223]. This became the rationale for combining these therapies with drugs
which reactivate p53 in p53-mutated cancers. There have been studies conducted on the combination
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of nutlin with ZMC1 (thiosemicarbazone). The authors hypothesized that if nutlin could stabilize
the levels of mutant p53, this will result in that ZMC1 should have more mutant p53 to reactivate
and in turn kill more cancer cells. The results of this combination therapy on immunodeficient mice
bearing TOV112D xenograft tumors have shown a significant synergistic effect on the tumor growth
inhibition in comparison to the single treatment [103].
4.6.5. Heat Shock Protein Inhibitor
Heat shock proteins (HSPs) are responsible for the proper folding of synthesized proteins or
refolding under denaturating conditions [224]. HSPs have an impact on protein degradation in
proteasome [225]. Cancer cells require HSP90 protein for the maintenance of mutated proteins.
In patients with acute myeloid leukemia, there is a high expression of HSPs [226]. Inhibitors of
Hsp90 increase the acetylation of p53 and inhibit HDMX, indicating the potential synergy with
HDM2 antagonists in enhancing p53-mediated apoptosis. Combination treatment of Hsp90 inhibitor
geldanamycin and nutlin-3 showed synergistic effect by inducing apoptosis in AML cell lines and
primary AML cells [104]. The results also revealed that nutlin-3 stimulates acetylation of p53,
histones, and heat shock proteins [104].
4.6.6. ATPase Inhibitors
Archazolid is a myxobacteria-derived ATPase inhibitor. The compound regulates anoikis
resistance and exhibits anti-tumor and anti-metastatic activity in hepatocellular carcinoma (HCC)
and breast cancer in both in vivo and in vitro models [227–229]. Schneider and colleagues have
reported that the archazolid/nutlin-3 combination results in synergistically induced cell death in
p53wt-harboring cancer cells in vitro and in a glioblastoma xenograft model [105]. The pro-apoptotic
effect was related to the activation of Bax and IGFBP3 (insulin-like growth factor-binding protein
3) pathways. It has also been disclosed that the observed synergy might be a consequence of the
reduction of glycolysis due to the intensified downregulation of TIGAR (TP53-inducible glycolysis
and apoptosis regulator) mRNA level and also diminished Glu1 levels and glucose uptake in cancer
cells [105].
4.6.7. Mitotic Inhibitors
Mitotic inhibitors, especially spindle poisons, are claimed to have a relatively low genotoxicity
score [230]. Spindle poisons were evaluated in pre-clinical trials as a single treatment, as well
as in combination with HDM2/p53 antagonists. Vincristine in combination with nutlin-3
increased anti-cancer activity in rhabdomyosarcoma (RMS) tumors harboring wild-type p53 [101].
Vincristine was also combined with RG7112 in infant mixed lineage leukemia-rearranged acute
lymphoblastic leukemia (MLL-ALL). There was a therapeutic enhancement in comparison compared
to the single therapy with RG7112 [106]. Paclitaxel, another example of spindle poisons, is currently
under evaluation in clinical trials in combination with ALRN-6924 (NCT03725436). This study is
being conducted on patients with advanced, metastatic, or unresectable solid tumors. It is a promising
strategy of anti-tumor therapy for patients with tumors which cannot be eliminated by the surgery.
4.6.8. Other Agents
Interestingly, metformin, a drug widely used in the treatment of type 2 diabetes mellitus
and polycystic ovary syndrome, seems to possess anti-tumor properties via indirect mTOR protein
inhibition [231,232]. One of the studies focused on combining metformin with nutlin-3a, and this
dual treatment of p53wt mesothelioma cells showed additive growth inhibition of the cells [107].
A combination of nutlin-3 and Tanshinone IIA, a phytochemical isolated from the Chinese medicinal
herb Salvia miltiorrhiza, seems to show a synergistic effect when used together in AML cell lines.
The authors reported increased cytotoxicity, apoptosis, autophagic cell death and cell cycle arrest,
as well as p53 upregulation and PI3K/Akt/mTOR pathway inhibition in the in vitro leukemiamodels
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and cell sampled from patients [108]. Within the antimetabolites group, there are analogs of folic acid
such as methotrexate. The compound inhibits key enzymes in nucleotide biosynthesis, leading to
cell-cycle arrest and apoptosis. Methotrexate combined with nutlin-3a resulted in a decline of
cytotoxicity evoked by nutlin-3 [42]. One additional study has shown that stapled peptideATSP-7041
has an additive effect on cytotoxicity and induction of cell death in Ewing’s sarcoma cells with USP7
inhibitor P5091 [57].
5. Conclusions
Undeniably, p53 is amongst the most important and best-studied proteins in the context of
cancer. Since the discovery of the cancer-preventing potential of p53 and its ubiquitous inactivation
in all types of cancers, multiple approaches aiming at its reactivation have been proposed [233]. The
development of small-molecule HDM2 antagonists has become one of the leading strategies in this
field since it was estimated that in around half of the cancers the wild-type status of the TP53 gene
is preserved.
Following the initial discovery of the nutlins, multiple chemical scaffolds were tested for the
ability to release p53 from HDM2 inhibition [31]. These extensive studies have produced several
extraordinary compounds, with proven bioactivity and optimized pharmacological properties that
were applicable for clinical trials. By that time, however, extensive evidence pointing to serious
limitations of the anticancer properties of HDM2 antagonists has accumulated, as these compounds
force p53 release without providing appropriate proapoptotic context. It seems that this judgment has
been well acknowledged for the past years. This is manifested by the extensive investigation of drug
combinations designed in order to support the anticancer properties of HDM2 antagonists (Figure 1).
Also, this trend has determined the direction of the experimental clinical trials, where multiple
combinations are tested in a search for potential therapeutic synergies. It seems only a matter of
time that some combinations will confirm their clinical relevance and will constitute new regimes for
the treatment of cancer patients.
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